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Abstract
The development of novel targeted therapies has become an important research focus for lung cancer treatment. Our
previous study has shown leptomycin B (LMB) significantly inhibited proliferation of lung cancer cells; however, p53 wild
type lung cancer cells were resistant to LMB. Therefore, the objective of this study was to develop and evaluate a novel
therapeutic strategy to sensitize LMB-resistant lung cancer cells by combining LMB and doxorubicin (DOX). Among the
different treatment regimens, pretreatment with DOX (pre-DOX) and subsequent treatment with LMB to A549 cells
significantly decreased the 50% inhibitory concentration (IC50) as compared to that of LMB alone (4.4 nM vs. 10.6 nM,
P,0.05). Analysis of cell cycle and apoptosis by flow cytometry further confirmed the cytotoxic data. To investigate
molecular mechanisms for this drug combination effects, p53 pathways were analyzed by Western blot, and nuclear
proteome was evaluated by two dimensional-difference gel electrophoresis (2D-DIGE) and mass spectrometry. In
comparison with control groups, the levels of p53, phospho-p53 (ser15), and p21 proteins were significantly increased while
phospho-p53 (Thr55) and survivin were significantly decreased after treatments of pre-DOX and LMB (P,0.05). The 2D-
DIGE/MS analysis identified that sequestosome 1 (SQSTM1/p62) had a significant increase in pre-DOX and LMB-treated cells
(P,0.05). In conclusion, our results suggest that drug-resistant lung cancer cells with p53 wild type could be sensitized to
cell death by scheduled combination treatment of DOX and LMB through activating and restoring p53 as well as potentially
other signaling pathway(s) involving sequestosome 1.
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Introduction
Lung cancer continues to be the leading cause of cancer death
worldwide and in the United States [1]. Non-small-cell lung
cancer (NSCLC) remains the predominant form of lung cancer
(about 85% of all lung cancers), among which lung adenocarci-
noma (AC) is the most frequent histologic subtype for all sexes and
races combined [2]. The prognosis of lung cancer is very poor,
with a 5-year survival rate of less than 15% in the United States.
Chemotherapy continues to be the most frequent treatment to
prolong survival and improve quality of life [3,4,5,6].
Cancer chemotherapy has been used successfully in a variety of
circumstances involving malignancies, however, its effectiveness
has often been limited by drug resistance and side effects [7].
Therapies focusing on specific molecule(s)/pathway(s) have the
potential to overcome these limitations [7]. Leptomycin B (LMB)
and/or its derivatives, which can efficiently inhibit nuclear export
by specifically inhibiting chromosome region maintenance 1
(CRM1), has been recognized as a novel class of cancer
therapeutics [8,9,10,11,12]. CRM1, the best characterized nuclear
export receptor, plays an essential role in canonical nuclear export
signal (NES)-dependent nuclear export, including major tumor
suppressor proteins (TSPs) such as p53, FOXO, pRB, p21, p27,
etc., as well as the inhibitor of NF-kB, namely I-kB [9,13]. Recent
studies have reported that CRM1 is expressed at a significantly
higher level in cervical cancer as compared to normal tissue [14]
and could serve as a prognostic factor for ovarian cancer [15] and
osteosarcoma [16]. Our recently published in vitro studies using
normal lung epithelial cells [17] and a bitransgenic mouse model
[18] have suggested that CRM1 plays a critical role in lung cancer
development. In addition, CRM1 was over-expressed in a tobacco
carcinogen-induced lung AC mouse model, and human lung AC
(unpublished data). These findings suggest CRM1 could serve as a
molecular target for cancer treatment, including lung cancer.
LMB is a highly specific and potent inhibitor of CRM1 function
by irreversibly binding with the sulfhydryl group of a Cys residue
near or within the cargo binding domain of CRM1 (alkylating Cys
528) [19,20]. Thus, LMB could prevent cytoplasmic localization
and modulate cancer-specific pathways, such as the inactivation of
important tumor suppressors like p53 [10]. Our recent study
demonstrated that lung AC cell line A549 (p53 wild type) was
more resistant to LMB than other cell lines with the p53 mutant or
null [12]. It is well known that p53 plays an important role in
promoting genomic stability, cell cycle arrest, apoptosis, DNA
repair, and senescence. Studies have suggested that the functions
of wild type p53 on cell growth arrest and DNA repair could
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32895increase resistance to radio- or chemo- therapeutic agents; it is also
prone to potentiate apoptosis in response to severe DNA damage
[21,22,23]. Therefore, to sensitize lung cancer cell to the
chemotherapeutic effect of LMB, we herein propose a therapeutic
strategy combining LMB with other drugs by inducing severe
DNA damage and p53 activation which could eventually lead to
increased function of p53 in apoptosis rather than in DNA repair.
Doxorubicin (DOX) is a widely used chemotherapeutic agent that
induces apoptosis in various cancer cells through activation of p53.
It has been used in the treatment of a variety of solid tumors.
However, drug resistance in DOX containing regimens is a major
issue which prevents better response rates and cures and
cardiotoxic side effects have been reported in cancer patients
treated with DOX [24,25,26]. Individual treatments of DOX
resulted in a strong resistance in many cancer cell lines including
A549, due to several mechanisms including drug bioavailability
[27,28] or NF-kB activation [29]. If DOX is combined with other
chemotherapeutic drugs, lower doses may be used to not only
reduce side effects, but also increase efficacy [30].
In this study, we sought to revert drug resistance to DOX and/
or LMB in A549 cells via different therapeutic regimens of a co-
treatment of DOX and LMB, as well as evaluate their possible
molecular mechanisms. We found that pretreatment of DOX with
the subsequent treatment of LMB sensitized the drug-resistant
A549 cells to the chemotherapeutic effect of LMB. These changes
might result from the initial activation of p53 by DOX treatment
and consequently CRM1 function blocking by LMB treatment to
accumulate activated p53 in the nuclear compartment. Further-
more, signaling pathways involving molecules other than p53
might also play important roles in promoting therapeutic effects of
the combined treatment of DOX and LMB.
Materials and Methods
Reagents
Doxorubicin (DOX) and dimethylsulfoxide (DMSO) were
purchased from Sigma-Aldrich Co. LLC, St. Louis, MO. LMB
(1 mM) was purchased from LC Labs, Woburn, MA. The stocks
of DOX (10 mg/mL) and LMB were diluted to the required
concentration immediately before use with growth media. 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
was purchased from USB Corporation. RPMI-1640 medium,
penicillin/streptomycin, and fetal bovine serum (FBS) were
purchased from Thermo scientific, Logan, UT. Primary antibod-
ies, including p53, phospho-p53 (Ser15), phospho-p53 (Thr55),
p21, sequestosome 1 (SQSTM1/p62), and survivin, were
purchased from Santa Cruz Biotechnology, Santa Cruz, CA.
Primary rabbit polyclonal anti-a-tubulin was purchased from
Abcam, Cambridge, MA. Horseradish peroxidase (HRP)-conju-
gated donkey anti-rabbit IgG and an enhanced chemilumines-
cence (ECL) kit were purchased from GE Healthcare, Piscataway,
NJ. Radioimmunoprecipitation assay (RIPA) lysis buffer was
purchased from Santa Cruz Biotechnology.
Cells and Cell Culture
Human lung adenocarcinoma epithelial cell lines A549 and
NCI-H358 were obtained from American Type Culture Collec-
tion (ATCC). The cells were cultured in RPMI-1640 medium
supplemented with 10% fetal bovine serum (FBS), 50 U/mL
penicillin, and 50 mg/mL streptomycin. The cells were incubated
at 37uC in a humidified incubator with 95% air and 5% CO2 by
volume. Cells were sub-cultured or plated for subsequent
treatment until they approached approximately 80% confluence.
Cell Viability Assay
Cell viability was evaluated using the MTT assay as previously
described [17]. Briefly, cells were plated at 5610
3 cells per well in
96-well plates. Based on the cytotoxicity of DOX or LMB
observed in this study and previous reports [9,12,26,31,32,33],
0.5 nM LMB or 0.5 mM DOX was selected for co-treatment or
pretreatment. The cells were treated with the following: 1) DOX
alone (0–5 mM) for 24 and 48 h; 2) LMB alone (0–10 nM) for 24
and 48 h; 3) co-treatment of 0.5 nM LMB and DOX (0–5 mM)
simultaneously (DOX+LMB (0.5 nM)) for 24 and 48 h; 4) co-
treatment of 0.5 mM DOX and LMB (0–10 nM) simultaneously
(LMB+DOX (0.5 mM)) for 24 and 48 h; 5) pretreatment of
0.5 nM LMB for 24 h (pre-LMB) and subsequent DOX (0–5 mM)
for 48 h (pre-LMB+DOX); and 6) pretreatment of 0.5 mM DOX
for 24 h (pre-DOX) and subsequent LMB (0–5 nM) for 48 h (pre-
DOX+LMB). Ethanol (EtOH, 0.1%) was used as the vehicle
control for LMB. Three hours before the end of each time point,
15 mL of MTT (10 mg/mL) was added to each well and incubated
at 37uC. At each time point, when purple precipitate was clearly
visible under the microscope, 100 mL of 100% DMSO was added
to all wells and cell viability was determined by measuring
absorbance at 570 nm (reference wavelength=630 nm) using a
SpectraMax Plus Spectro-photometer (Molecular Devices, Sunny-
vale, CA). Six replicates at each concentration and time point were
analyzed. Experiments were performed independently in tripli-
cate. Vehicle-treated controls and blanks were incubated in the
same plate under the same conditions. Fractional absorbance was
calculated by using the following formula: % cell viability=mean
absorbance in test wells/mean absorbance in control wells 6100.
Analysis of Cell Cycle and Apoptosis by Flow Cytometry
Cells were first given pretreatment of 0.5 mM DOX for 24 h
and then were treated with LMB for additional 48 h. Therefore,
the cells were harvested after a total of 72 h of treatment. Based on
the cell viability assay, a total of 6 groups of A549 cells with
different treatments were analyzed, including control, 0.5 mM
DOX (pre-DOX), 1 nM LMB (LMB1), pre-DOX and 1 nM
LMB (pre-DOX+LMB1), 5 nM LMB (LMB5), and pre-DOX and
5 nM LMB (pre-DOX+LMB5). For cell cycle analysis, a total of
2610
5 cells from each treatment group were collected and fixed in
70% ethanol for more than 24 h at 4uC. Cells were stained with
Guava Cell Cycle Reagent (Millipore) and run on a Guava
EasyCyte
TM Flow Cytometer (Millipore). A total of 5610
3 events
were counted, and the percentage of cells in the pre-G1, G0/G1,
S, and G2/M phases of the cell cycle were determined using
GuavaSoft software (Millipore). For apoptosis analysis, ViaCount
assay was performed to determine viable and dead cells. In brief,
the cell suspension (5610
5 cells/mL) was mixed with Guava
ViaCount reagent (Millipore), and the mixture was incubated at
room temperature for 5 minute to stain cells. The stained cell
samples were run on a Guava EasyCyte
TM Flow Cytometer
(Millipore). A total of 5610
3 events were counted and data were
acquired using Guava ViaCount software (Millipore). Each sample
was run in triplicate and each experiment was repeated three
times.
Western Blot
The same 6 treatment groups of A549 cells as described in the
flow cytometry were analyzed for Western blot. Cells in each
group were lysed in RIPA lysis buffer on ice. The lysates were
sonicated and then centrifuged at 13,0006g for 5 min at 4uCt o
collect the supernatant. Protein concentrations were measured
using the Bio-Rad Bradford protein assay. A total of 30 mgo f
protein per sample was separated by 12% SDS-polyacrylamide gel
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dene fluoride (PVDF) membranes. The immobilized proteins were
then incubated overnight at 4uC in blocking buffer containing 3%
nonfat dry milk in 16phosphate buffered saline (PBS) and 0.1%
Tween 20 (16 PBST). After blocking, the membranes were
probed with the primary antibody for 1 h. Antibody binding was
detected with donkey anti-rabbit IgG-HRP at a dilution of 1:1,000
for 1 h at room temperature. After a brief incubation with ECL,
the signals on membranes were exposed to X-ray films (Fujifilm
Corporation, Tokyo). Relative densitometric digital analysis of
protein bands were determined using Quantity One software (Bio-
Rad) and normalized by the intensity of the housekeeping gene (a-
Tubulin, 1:10,000 dilution) for each sample.
Effects of DOX and LMB on Nuclear Protein Profile
To evaluate the effects of DOX and LMB on proteins besides
those in the p53 pathway, a gel-based proteomic approach, two
dimensional-difference gel electrophoresis (2D-DIGE), was first
performed to investigate nuclear protein profiles after LMB
treatment. Protein spots showing major changes were identified by
liquid chromatography mass spectrometry (LC/MS/MS) and
confirmed by Western blot. Changes in protein(s) were further
evaluated in cells with combined treatment of DOX and LMB by
Western blot.
Nuclear Protein Extraction. For proteomic analysis, nuclear
proteins were extracted following the protocols as described by Lu et
al [34]. In brief, based on our previous study [12], A549 or NCI-
H358 cells, treated with vehicle control (0.1% EtOH) or 20 nM
LMB for 24 h (in duplicate), were rinsed with ice-cold PBS,
harvested, and suspended in ice-cold Buffer A containing 10 mM
tris-HCl (pH: 7.4, Bio-Rad), 8 M Urea (Bio-Rad), 4% (w/v) 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS,
Bio-Rad), 0.5 mM ethylenediaminetetraacetic acid (EDTA, Bio-
Rad), 2.5 mM MgCl2 (EMD Chemicals, Gibbstown, NJ), 0.5 mM
PMSF (Santa Cruz Biotechnology), 16 protease inhibitor cocktail
(Roche,Basel,Switzerland),and1%(v/v)NP-40(USBCorporation,
Cleveland, OH). The mixture was homogenized with a 21-gauge
needle, followed by centrifuging the homogenate at 7006 gf o r
10 min at 4uC to precipitate the nuclei. The cytoplasmic extracts in
supernatants were collected and pellets were resuspended in 1 mL of
ice-cold Buffer B (20 mM tris-HCl, pH 8.5 and 16 protease
inhibitor cocktail), sonicated on ice, and mixed with 0.737 g urea,
0.267 g thiourea, and 0.07 g (w/v) CHAPS. After incubation on ice
for 1 h, supernatants containing nuclear extracts were collected by
centrifugation at 100,0006gf o r1ha t4 uC. Protein concentrations
were measured by the Bradford assay (Bio-Rad). The quality of
nuclear extraction was determined, and the identified protein was
confirmed by Western blots. a-tubulin (present in cytoplasm) and
histone 3 (present in nucleus) were used to validate and confirm the
purity of protein fractions.
2D-DIGE. Nuclear protein extractions for 2D-DIGE were
run as previously described [35]. In brief, nuclear protein
extractions from A549 or NCI-H358 cells with or without LMB
treatment (in duplicate) were reversely labeled with Cy3 and Cy5,
respectively (GE Healthcare). Tubes containing 50 mg of each
sample were combined with 1 mL of diluted Cy3 or Cy5
(400 pmol/mL in N,N-dimethylformamide, Sigma). After
centrifugation, the mixture was left on ice for 30 min without
light exposure. Thereafter, the reaction was stopped by the
addition of 1 mL of 10 mM lysine (Sigma) and placement of
samples on ice for 10 min in the dark. Samples (containing 100 mg
proteins) labeled with Cy3 and Cy5, were diluted to 300 mLb y
adding 2D rehydration buffer (BioRad) consisting of 8 M urea,
0.5% CHAPS, 10 mM dithiothreitol (DTT, Bio-Rad), 0.2%
biolytes ampholyte, and trace bromophenol blue. Samples were
then applied to 17-cm immobilized linear pH 3–10 gradient (IPG)
strips (BioRad) for overnight rehydration. Isoelectric focusing was
conducted at 250 V for 20 min, gradually increased to 10,000
within 2.5 h, and held at 10,000 V for a total of 50,000 Voltage
hours (Vh). IPG strips were subsequently equilibrated with buffer I
(6 M urea, 2% SDS, 375 mM tris-HCl (pH 8.8), 20% glycerol,
130 mM DTT, and trace bromophenol blue) and buffer II (6 M
urea, 2% SDS, 375 mM Tris-HCl, 20% glycerol, 135 mM
iodoacetamide, and trace bromophenol blue). Proteins were then
separated with 12% SDS-PAGE gels and visualized using a
Typhoon Trio Imager (GE Healthcare) at excitation wavelengths
of 532 and 633 nm for Cy3 and Cy5, respectively. Images were
manipulated and analyzed by DeCyder and ImageQuant software
(GE Healthcare); protein intensity differences were calculated for
each spot on every gel.
In-gel Digestion. The 2D gels were stained with SYPRO-
RUBY (Bio-Rad). Spots of interest were isolated using a spot
picker, and placed into a 0.5 mL Eppendorf tube for trypsin
digestion on a ProGest (Genomic solutions) workstation [35]. In
brief, gel plugs were washed with diH2O, and treated with
acetonitrile (ACN) for 15 min. The gel pieces were rehydrated
with 10 mM DTT and 0.1 M ammonium bicarbonate
(NH4HCO3) for 30 min at 60uC in water bath. Following
shrinkage again with ACN, a solution containing 55 mM
iodoacetamide (Bio-Rad) and 0.1 M NH4HCO3 was added for
20 min without light exposure, then replaced by 0.1 M
NH4HCO3 for 15 min. The gel plugs were subsequently washed
in 0.1 M NH4HCO3 for 5 min, while adding an equal volume of
ACN for 5 min. After repeating the wash step twice, the gel pieces
were dehydrated by ACN, and then dried for 30 min. Individual
gel pieces were rehydrated in digestion buffer containing 12.5 ng/
mL trypsin (Promega), 40 mM NH4HCO3, and 10% ACN at
37uC for 4 h. Formic acid was added to stop the reaction and the
supernatant was analyzed directly.
LC/MS/MS Identification. Trypsinized peptides were
analyzed by nano LC/MS/MS on a ThermoFisher LTQ
Orbitrap XL. In brief, 30 mL of hydrolysate was loaded onto a
5m m 675 mm ID C12 (Jupiter Proteo, Phenomenex) vented
column at a flow-rate of 10 mL/min. Gradient elution was
conducted on a 15 cm by 75 mm ID C12 column at 300 nL/
min. A 30 min gradient was employed. The mass spectrometer
was operated in a data-dependent mode, and the six most
abundant ions were selected for MS/MS. Mass spectrometry
results were searched using Mascot (www.matrixscience.com).
Samples were processed in the Scaffold algorithm using DAT files
generated by Mascot. Parameters for LTQ Orbitrap XL data
require a minimum of 2 peptide matches per protein with
minimum probabilities of 90% at the protein level.
Statistical Analyses
Factorial ANOVA was performed to test the effects of DOX
and/or LMB concentrations and incubation times on cell viability.
Probit analysis was used to calculate the 50% inhibitory
concentrations (IC50s). For the data obtained from flow
cytometry, the average cell percentages were calculated and
statistical significance was determined via one-way ANOVA and
post hoc tests. For the protein expression levels among control,
pre-DOX, LMB1, pre-DOX+LMB1, LMB5, and pre-
DOX+LMB5, one-way ANOVA and Tukey’s post hoc tests were
used to compare densitometric intensity of individual samples
between groups. For 2D-DIGE, image analysis was carried out
with DeCyder software (GE Healthcare) and ImageMaster
software. For DeCyder software, the Differential In-Gel Analysis
Combination Therapy of LMB and DOX
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gel, and perform spot detection and quantification. The Biological
Variation Analysis (BVA) was employed to calculate ratios
between samples and controls by performing a gel-to-gel matching
of the pair of spot maps from each gel. The spots with more than a
two-fold change in reverse-labeled duplicated experiments as
compared with controls were considered as target proteins. All
analyses were performed using SPSS software (SPSS, Inc.,
Chicago, IL, USA) and differences with P,0.05 were considered
statistically significant.
Results
Cytotoxicity of DOX or LMB
The MTT assay was performed to determine cell viability at
each time point. As shown in Figure 1A and 1B, both DOX and
LMB significantly inhibited cell proliferation of A549 in a dose-
and time- dependent manner (P,0.001). The IC50s of DOX and
LMB at 48 h were 2.2 mM and 10.6 nM, respectively (Table 1).
Similarly, both DOX and LMB significantly inhibited cell
proliferation of NCI-H358 in a dose- and time- dependent
manner (P,0.001, Figure S1A and S1B).
Cytotoxicity of Co-treatment of DOX and LMB
Similar to DOX or LMB groups, DOX+LMB (0.5 nM) or
LMB+DOX (0.5 mM) inhibited A549 proliferation in a dose- and
time- dependent manner (P,0.001, Figure 1A and 1B). However,
the simultaneous treatments of DOX+LMB (0.5 nM) or
LMB+DOX (0.5 mM) did not change the cytotoxic effects on
A549 cells as compared to DOX alone or LMB alone at both 24
and 48 h (P.0.05, Figure 1A and 1B). The IC50s of DOX+LMB
(0.5 nM) and LMB+DOX (0.5 mM) at 48 h were 2.1 mM and
10.4 nM, respectively (Table 1). Similarly, the simultaneous
treatments of DOX+LMB (0.5 nM) or LMB+DOX (0.5 mM) did
not change the cytotoxic effects on NCI-H358 cells as compared to
DOX alone or LMB alone at both 24 and 48 h (P.0.05, Figure
S1A and S1B).
Cytotoxicity of pre-LMB+DOX or pre-DOX+LMB
As shown in Figure 1C, pretreatment of 0.5 nM LMB did not
boost the cytotoxic effects of DOX on A549 cells at 48 h as
compared with DOX alone (P.0.05). The IC50s at 48 h of pre-
LMB+DOX and DOX alone were 2.8 and 2.2 mM, respectively
(Table 1). However, the pretreatment of 0.5 mM DOX signifi-
cantly increased the cytotoxic effect of LMB on A549 cells at 48 h
(P,0.05, Figure 1D). The IC50 at 48 h of pre-DOX+LMB was
4.4 nM, which was significantly lower than that of LMB alone
(10.6 nM, P=0.037, Table 1). Furthermore, either pre-LMB or
pre-DOX did not improve the cytotoxic effects of DOX or LMB
on NCI-H358 cells (P.0.05, Figure S1C and S1D).
Effects of DOX and LMB on Cell Cycle and Apoptosis
Cell proliferation inhibition could be the result of either cell
cycle arrest or apoptosis, thus these two aspects were further
examined by flow cytometry analysis of A549 cells after LMB and
DOX treatment. The cell cycle analysis revealed that the
percentage of cells in G2/M were 15.160.4, 26.962.8, 22.76
1.0, 22.964.2, 22.562.8, and 18.661.3 in the control, pre-DOX,
LMB1, pre-DOX+LMB1, LMB5, and pre-DOX+LMB5, respec-
tively (Table 2). Pre-DOX, LMB1, pre-DOX+LMB1, LMB5, and
pre-DOX+LMB5 all resulted in an accumulation in the G2/M
phase versus control (P,0.05, Figure 2 and Table 2). In addition,
the cell cycle analysis revealed that the percentage of cells in pre-
G1 were 5.462.2, 9.062.1, 8.262.0, 18.667.1, 10.264.7, and
27.562.8 in the control, pre-DOX, LMB1, pre-DOX+LMB1,
LMB5, and pre-DOX+LMB5, respectively (Table 2). Pre-
DOX+LMB1 and pre-DOX+LMB5 resulted in a definitive
accumulation in the pre-G1 phase versus not only control but
also LMB alone (P,0.01, Figure 2 and Table 2). Analysis of
apoptosis revealed that LMB treatment significantly induced cell
apoptosis (P,0.01, Table 2). Apoptosis was further increased after
cells were co-treated with pre-DOX and LMB compared with
LMB alone (P,0.01, Table 2). The percentage of apoptotic cells
were 13.261.6, 15.862.6, 19.262.4, 27.160.6, 22.464.0, and
29.662.1 in the control, pre-DOX, LMB1, pre-DOX+LMB1,
LMB5, and pre-DOX+LMB5, respectively (Table 2).
Western Blot Analyses of p53, Phospho-p53 (Ser15),
Phospho-p53 (Thr55), p21, and Survivin Protein
Expression after DOX and LMB Treatment
Expression levels of p53, phospho-p53 (Ser15), and p21 (a
downstream target of p53) were significantly increased in cells
treated with pre-DOX+LMB than those of controls and showed a
significant dose-response effect (Figure 3A). The relative protein
expression levels of p53 (arbitrary units) were 0.0260.00,
0.0360.00, 0.0760.00, 0.1360.03, 0.4560.01, and 0.4460.00
in the control, pre-DOX, LMB1, pre-DOX+LMB1, LMB5, and
pre-DOX+LMB5, respectively (Figure 3B, P,0.05, LMB1 vs.
control; P,0.01, pre-DOX+LMB1, LMB5, or pre-DOX+LMB5
vs. control). The relative protein expression levels of phospho-p53
(Ser15) (arbitrary units) were 0.0660.00, 0.0660.00, 0.1360.03,
0.1560.01, 0.2160.01, and 0.7760.04 in the control, pre-DOX,
LMB1, pre-DOX+LMB1, LMB5, and pre-DOX+LMB5, respec-
tively (Figure 3B, P,0.05, LMB5 vs. control; P,0.01, pre-
DOX+LMB5 vs. control). Furthermore, the up-regulation of
phospho-p53 (Ser15) in pre-DOX+LMB5 was significant com-
pared with the LMB5 group (P,0.01). Relative protein expression
levels of p21 (arbitrary units) were 0.2960.08, 0.6960.01, 0.856
0.09, 1.0760.03, 1.1460.08, and 1.5760.02 in the control, pre-
DOX, LMB1, pre-DOX+LMB1, LMB5 and pre-DOX+LMB5,
respectively (Figure 3B, P,0.01, pre-DOX, LMB1, pre-DOX+
LMB1, LMB5, and pre-DOX+LMB5 vs. control). Furthermore,
the up-regulation of p21 in pre-DOX+LMB5 was significant
(P,0.05) compared with the LMB5 group.
Contrary to p53, phospho-p53 (Ser15), and p21 expression levels,
phospho-p53 (Thr55) and survivin (another downstream target of
p53) expression levels were significantly and dose dependently
decreased in cells treated with pre-DOX+LMB compared to those
of controls (Figure 3A). The relative protein expression levels of
phospho-p53 (Thr55) (arbitrary units) were 0.6760.06, 0.5660.01,
0.6560.01, 0.5760.00, 0.5660.01, and 0.4260.00 in the control,
pre-DOX, LMB1, pre-DOX+LMB1, LMB5, and pre-DOX+
LMB5, respectively (Figure 3B, P,0.01, pre-DOX+LMB5 vs.
control). The relative protein expression levels of survivin (arbitrary
units) were 0.2860.02, 0.2360.03, 0.2360.05, 0.1460.01,
0.1260.05, and 0.0860.00 in the control, pre-DOX, LMB1, pre-
DOX+LMB1, LMB5, and pre-DOX+LMB5 treated groups,
respectively (Figure 3B, P,0.05, pre-DOX+LMB5 vs. control).
Effects of DOX and LMB on Nuclear Protein Profile
Nuclear Protein Extraction. Purity of the nuclear and
cytoplasmic proteins was tested using Western blot analysis with
anti-histone 3 and anti-a-tubulin. Majority of a-tubulin was found
only in the cytoplasmic fraction from A549 and NCI-H358 cells;
histone 3 was found only in the nuclear fraction from A549 and
NCI-H358 cells, suggesting that the preparation was enriched for
nuclear proteins (Figures 4A and S2A).
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32895Figure 1. Cytotoxic effects of DOX and LMB on A549 cells. A, Cytotoxic effects of DOX alone and DOX+LMB on cell viability of A549 cells as
determined by the MTT assay. Data are expressed as the percentage by comparing to vehicle control for DOX and LMB (0.5 nM) for DOX+LMB. Values
are represented as means 6 SD, n=6. B, Cytotoxic effects of LMB alone and LMB+DOX on cell viability of A549 cells as determined by the MTT assay.
Data are expressed as the percentage by comparing to vehicle control for LMB and DOX (0.5 mM) for LMB+DOX. Values are means 6 SD, n=6. C,
Cytotoxic effects of DOX alone and pre-LMB+DOX on cell viability of A549 cells at 48 h as determined by the MTT assay. Data are expressed as the
percentage by comparing to vehicle control for DOX and pre-LMB for pre-LMB+DOX. Values are means 6 SD, n=6. D, Cytotoxic effects of LMB alone
and pre-DOX+LMB on cell viability of A549 cells at 48 h as determined by the MTT assay. Data are expressed as the percentage by comparing to
vehicle control for LMB and pre-DOX for pre-DOX+LMB. Values are means 6 SD, n=6. Experiments performed in triplicate yielded similar results.
doi:10.1371/journal.pone.0032895.g001
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in nuclear extractions of A549 cells. Duplicate DIGE gels with
reverse label were run and showed more than 99% between-gel
reproducibility. From these detected spots, 13 spots showed more
than or equal to two-fold increase in LMB-treated A549 cells, out
of that 5 spots with the highest changes had almost the same
molecular weight (MW, approximate 60 kDa) but different
isoelectric point (PI), suggesting the possibility of post-
translational modifications (PTMs) of the same protein
(Figure 4B). On the other hand, among the approximate 1,000
protein spots detected in nuclear extraction of NCI-H358 cells, no
proteins spots showed significant changes (Figure S2B).
Protein Identification by LC/MS/MS and Western Blot
Analysis of SQSTM1. Among the total 13 spots of interest, only
3 spots were visible by SYPRO-RUBY staining. The visible spots
were among the earlier 5 spots with the same MW but different PI
and had the highest changes. They were identified as SQSTM1 by
LC/MS/MS. For instance, there were 9 matched peptides (27%
sequence coverage) from the LC/MS/MS for the spot with the
most hits (Figure 4C). To confirm and validate the results of 2D-
DIGE/MS, Western blot analysis was performed. The expression
of SQSTM1 in LMB-treated A549 cells was significantly increased
in comparison with control cells in both nucleus and cytoplasm of
Table 1. Cytotoxicity of DOX and LMB on A549 cells.
Treatment 1 Treatment 2 IC50s
DOX at different
concentrations (0–5 mM)
None 2.2 mM
0.5 nM LMB simultaneously 2.1 mM
0.5 nM LMB 24 h earlier 2.8 mM
LMB at different
concentrations (0–5 nM)
None 10.6 nM
0.5 mM DOX simultaneously 10.4 nM
0.5 mM DOX 24 h earlier 4.4 nM*
*P,0.05 in comparison to LMB alone or LMB+0.5 mM DOX simultaneously.
doi:10.1371/journal.pone.0032895.t001
Figure 2. Flow cytometry analyses of cell cycle and apoptosis in A549 cells after DOX and LMB treatment. Representative histograms of
cell cycle analyses in DOX and LMB-treated A549 cells. Control, pre-DOX, LMB1, pre-DOX+LMB1, LMB5, and pre-DOX+LMB5 were harvested and
labeled with Guava Cell Cycle Reagent (Millipore) and analyzed by flow cytometry (pre-G1, G0/G1, S, and G2/M). The y-axis shows the number of cells
counted and the x-axis shows an increasing amount of Guava Cell Cycle Reagent incorporation/cell (left to right). Experiments performed in triplicate
yielded similar results. LMB1: 1 nM LMB, LMB5: 5 nM LMB.
doi:10.1371/journal.pone.0032895.g002
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cells was not changed in both nucleus and cytoplasm of cells
(Figure S2C).
Effects of DOX and LMB on SQSTM1 Protein
Expression. Western blot analysis was performed to analyze
SQSTM1 protein expression level (Figure 4E). The relative
protein expression levels of SQSTM1 (arbitrary units) were
0.0860.01, 0.1360.06, 0.1060.02, 0.1060.02, 0.9560.02 and
1.0960.10 in the control, pre-DOX, LMB1, pre-DOX+LMB1,
LMB5 and pre-DOX+LMB5, respectively (Figure 4E). The up-
regulations of SQSTM1 in LMB5 and pre-DOX+LMB5 treated
cells were significant compared with control cells (P,0.001). In
addition, SQSTM1 was slightly but not significantly higher in pre-
DOX+LMB5 than that of LMB5 alone.
Discussion
LMB and/or its derivatives have been recognized as a novel
class of cancer therapeutics through highly specific and potent
inhibition of CRM1, a NES-dependent nuclear exporter
[8,9,10,11,12,19,20]. Our previous study found that LMB could
significantly inhibit cell proliferation of various lung AC cell lines
compared to normal lung epithelial cells [12]. However, A549 cells
(with p53 wild type) were more resistant to doses that were
effective in other lung AC cell lines and the IC50 of LMB on A549
was close to that of normal lung epithelial cells. Combination
chemotherapy could increase the therapeutic efficacy, decrease
toxicity to normal cells with lower dosage, and minimize or delay
the development of drug resistance. DOX is another cancer
therapeutic drug, however, lung AC cells with p53 wild type, such
as A549 cells, are resistant to this drug [28]. Due to DOX’s specific
molecular activity including p53 up-regulation and/or activation
mediated apoptosis [24,26,31], it was used in this study to test its
efficiency in combination with LMB treatment to sensitize the
drug resistance of A549 to the chemotherapeutic effect of LMB.
Our results for the first time report increased drug efficacy from
the combined therapy of an initial DOX treatment and
subsequent LMB treatment in A549 cells, but not in p53 null
NCI-H358 lung AC cells. The findings of this study also revealed
that simultaneous treatment of LMB and DOX, or pretreatment
of LMB with subsequent treatment of DOX was not effective in
A549 cells (similar in p53 null NCI-H358 lung AC cells). These
results indicate that pretreatment with DOX is required for
chemotherapeutic inhibition of lung AC cells and the interaction
between DOX and LMB is highly schedule dependent. Further-
more, our results reveal that the molecular mechanisms involving
p53 activation and other signaling protein(s)/pathway(s) involving
sequestosome 1 could be the pre-requisite trigger to the observed
effectiveness of combination therapy.
As expected, we found that both DOX and LMB have
significant inhibitory effects on A549 cells in a dose- and time-
dependent manner. The IC50 value of DOX observed in this
study was comparable to previous reports that showed IC50s of 1–
5 mM in A549 cells [32,36]. Among the four regimens tested, only
pre-DOX treatment could boost the cytotoxic effect of LMB, in
which the IC50 decreased more than 2-fold. The total duration of
sequential treatment of pre-DOX+LMB or pre-LMB+DOX was
72 h that includes 24 h of pretreatment and subsequent 48 h of
co-exposure. The doses chosen for pre-LMB or pre-DOX did not
show significant cytotoxic effects to A549 cells at 24–72 h.
Nevertheless, the sequential treatment data were analyzed by
using pre-LMB or pre-DOX as controls with their respective
durations of exposure to exclude the potential cytotoxic effects
from pre-LMB or pre-DOX. In addition, co-treatment of LMB
and DOX for 72 h did not boost the cytotoxic effects of either
LMB or DOX for both A549 and H358 cells (data not shown).
Results from flow cytometry analysis further validated the
cytotoxicity data. Both DOX and LMB treatment decreased the
fraction of cells in G0/G1 and S phases while they increased the
fraction of cells in G2/M phases, suggesting G2/M arrest of
DOX/LMB-treated A549 cells. These observations are consistent
with previous findings of DOX induced predominant G2 arrest
[37] and LMB producing reversible G1 and G2 arrest [38].
Interestingly, although the number of cells in G2/M phase was not
changed in cells treated with pre-DOX and LMB compared to
LMB alone, the number of cells at pre-G1 phase was significantly
increased in A549 cells treated with pre-DOX and LMB
compared to LMB alone. Furthermore, the number of apoptotic
cells was also significantly increased in cells treated with pre-DOX
and LMB compared to LMB alone. Together, these data suggest
pre-DOX treatment enhanced or facilitated the effect of LMB on
mitotic arrest. Individual treatments by DOX itself caused
predominantly G2/M arrest while pre-DOX and LMB induced
predominantly apoptosis. In addition, apoptosis increased with
increasing concentrations of LMB.
DOX is generally classified as a topoisomerase II inhibitor that
induces DNA double-strand breaks. DOX, although not frequent-
ly used in recent lung cancer protocols but commonly used to treat
other cancers such as leukemias, lymphomas, as well as other solid
tumors [29,33,39]. The cellular response to DNA damage, which
Table 2. Effects of DOX and LMB on cell cycle and apoptosis of A549 cells.
Cell Cycle (%) Apoptosis (%)
Pre-G1 G0/G1 S G2/M
Control 5.462.2 74.562.9 5.060.9 15.160.4 13.261.6
Pre-DOX 9.062.1 61.661.7** 2.560.7** 26.962.8** 15.862.6
LMB1 8.262.0 66.661.5** 2.560.1** 22.761.0** 19.262.4**
Pre-DOX+LMB1 18.667.1**## 57.262.8**## 1.260.1**# 22.964.2** 27.160.6**##
LMB5 10.264.7 65.061.7** 2.360.3** 22.562.8** 22.464.0**
Pre-DOX+LMB5 27.562.8**## 52.561.9**## 1.560.2**# 18.661.3*# 29.662.1**##
*P,0.05 in comparison to control;
**P,0.01 in comparison to control.
#P,0.05 in comparison to LMB alone;
##P,0.01 in comparison to LMB alone.
doi:10.1371/journal.pone.0032895.t002
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32895Figure 3. Western blot analyses of protein expression in A549 cells after DOX and LMB treatment. A, Effects of pre-DOX+LMB treatment
on the protein expression of p53, phospho-p53 (Ser15), phospho-p53 (Thr55), p21, and survivin in A549. Cells were treated with 0.5 mM DOX 24 h
before treatment with LMB (1 nM or 5 nM). After 48 h LMB treatment, cells were harvested for Western blot analysis to determine protein levels. Blots
were also probed for a-tubulin to confirm equal protein loading. B, The relative protein intensities of p53, phospho-p53 (Ser15), phospho-p53 (Thr55),
p21, and survivin as compared with the intensity of a-tubulin. The intensity of each band was quantified using Quantity One software. Data are
means 6 SD, n=3. The experiments were conducted in triplicate. LMB1: 1 nM LMB; LMB5: 5 nM LMB; *, P,0.05 compared to control; **, P,0.01
compared to control; #, P,0.05, compared to LMB5; ##, P,0.01, compared to LMB5.
doi:10.1371/journal.pone.0032895.g003
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using DOX [33]. Thus, the better understanding of the
combination effects of DOX with other potential targeted
chemotherapies, such as LMB, will lead a significant clinical
milestone which can eventually overcome drug resistance. Our
previous study has also suggested that p53 signaling pathway was
activated after LMB treatment in A549 cells [12]. p53 can be
activated through post-translational modifications such as phos-
phorylation, as well as subcellular localization. The phosphoryla-
tion sites have been identified at multiple locations on both N-
terminus and C-terminus of p53 [40]. It is recognized that an early
critical event in the stabilization and activation of p53 in response
to genotoxicity is the phosphorylation of Ser15 through activation
of ATM in response to DNA damage [41]. In the present study,
Western blot data demonstrated that LMB was very effective in
induction of both total p53 and p53 phosphorylation at Ser15
compared to the control. In addition, phospho-p53 at Ser15 was
increased in cells treated with pre-DOX and LMB (5 nM)
compared to LMB (5 nM) alone. Nuclear export of p53 is
mediated by CRM1; this can be abrogated by LMB [9,11,12].
Thr55 is another important phosphorylation site for p53 function
because of its location at the amino acid 43–63 residues of p53 that
contain an apoptotic and growth suppression domain [42,43]. In
other studies, inhibition of Thr55 phosphorylation of p53 restored
its nuclear localization and sensitized cancer cells to DNA damage
[44]; the phosphorylation of Thr55 led to p53 degradation and a
decrease in G1 arrest of the cell cycle [45]. The decreased
phospho-p53 (Thr55) after pre-DOX and LMB treatment
observed in this study was in agreement with these previous
findings and was further confirmed by data on cell viability and
Figure 4. Nuclear proteome profiling in A549 cells after DOX and/or LMB treatment. A, Western blot of nuclear and cytoplasmic protein
extractions from A549; a-tubulin served as an internal control for cytoplasmic proteins, and histone 3 served as a control for nuclear proteins. B, 2D-
DIGE analyses of nuclear proteins in A549 cells and 3D views of SQSTM1 in A549 cell with vehicle control or LMB treatment. Nuclear proteins treated
with LMB or vehicle control were labeled with Cy3 (green channel) and Cy5 (red channel), respectively. Nuclear proteins were separated based on
isoelectric point (PI, horizontal axis) and molecular weight (MW, vertical axis). Approximately 1,000 protein spots were detected in nuclear extractions
of A549 cells. Spots labeled with red color indicate decreased expression after LMB treatment, while spots labeled with green color indicate increased
expression after LMB treatment (left panel). Magnification of 5 protein spots (right upper panel) and 3D view of vehicle control and LMB treated (right
bottom panel) (identified by LC/MS/MS as sequestosome 1 (SQSTM1/p62)). C, Protein sequence and tandem mass spectrometry identification of
SQSTM1. The MS/MS fragmentation spectrum (obtained after trypsin digestion) of AYLLGKEDAAR for SQSTM1 is shown. The resultant MS/MS data
were processed using Mascot. D, Western blot analysis of SQSTM1 in cytoplasm and nucleus of A549 cells after LMB treatment. E, Effects of LMB alone
or pre-DOX+LMB treatment on protein expression of SQSTM1 in A549 cells. The relative protein intensity of SQSTM1 was compared with the intensity
of corresponding a-tubulin. The intensity of each band was quantified using Quantity One software. Data are means 6 SD. Experiments were
conducted in triplicate. LMB1: 1 nM LMB; LMB5: 5 nM LMB; **, P,0.001 compared to control.
doi:10.1371/journal.pone.0032895.g004
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have shown that LMB could increase the activation/stabilization/
nuclear accumulation of p53 by blocking its nuclear export
through CRM1 [9,12,46,47,48,49,50]. This could further lead to
the increased expression of p53 downstream target genes, such as
p21 [12,49,50]. It has also been reported that phosphorylated
Ser15 of p53 localized in the nucleus [51]. Moreover, consistent
with these previous findings, we also observed the p53 and
phospho-p53 (Ser15) accumulated in the nuclear compartment
after LMB treatment as determined by western blot analysis using
nuclear/cytoplasmic protein fractions from A549 cells (data not
shown). Besides LMB, DOX treatment could also induce nuclear
accumulation of p53 [31,52,53]. Taken together, these evidences
suggested that the superior cytotoxic effect of pre-DOX+LMB
could be attributed to nuclear accumulation of p53. In addition,
our results of p53 expression also suggest that phosphorylation on
Ser15 and Thr55 sites of p53 may cooperatively regulate the
stability of p53 and thereby more effectively activate p53 in
response to DOX and LMB treatment. The treatment regimen of
pretreatment of DOX and LMB, but not DOX and LMB
simultaneously or pretreatment of LMB and subsequent DOX,
could induce and activate p53 in the function of apoptosis rather
than DNA repair that led to the drug sensitization of A549 cells.
The regulation of protein expression of p53 target genes
involved in cell growth suppression and apoptosis was also
observed after DOX and LMB treatment. For example, p21, a
downstream target of p53, was elevated at the protein level after
DOX and LMB treatment, especially in cells treated with pre-
DOX and LMB. This elevated level of p21 could result in
hypophosphorylation of the Rb protein, which in turn binds with
E2F transcription factor and subsequently blocks the cell cycle
[54,55]. Besides p53, survivin expression was significantly
repressed after LMB treatment, especially when pretreatment of
DOX was applied before LMB. Survivin, a member of the
inhibitor of apoptosis family of proteins, is negatively regulated by
wild type p53 and plays an important role in regulation of both
apoptosis and cell division [56]. Survivin repression caused by
DNA damage may decide whether the damaged cells would die
before DNA repair is accomplished by activating the p53-
dependent G2/M checkpoint [57]. Moreover, nuclear export of
p21 and survivin is CRM1-mediated [58,59]. Thus, LMB may
directly or indirectly modulate the expression of p21 and survivin.
Collectively, the elevated level of p21 and repression of survivin
were consistent with the cytotoxicity, cell cycle/apoptosis, and p53
activation after DOX and LMB treatment. The combined therapy
of an initial DOX treatment (for activation of p53) and subsequent
LMB treatment (for blocking CRM1 function to increase and
accumulate activated steady-state level of p53 in the cellular
nucleus) might be one reason for the increased effectiveness.
SQSTM1 (p62) had been identified by a proteomic approach
using 2D-DIGE and MS as a possible new protein(s)/pathway(s)
that could be targeted by LMB treatment in p53 wild type A549
cells but not p53 null NCI-H358 cells. SQSTM1 was first
described in 1995 as a phosphotyrosin-independent ligand of the
src homology 2 (SH2) domain of the lymphoid-specific src family
tyrosine kinase p56Ick [60]. SQSTM1 was recently shown to be
continuously shuttled between the cytoplasm and nucleus at a high
rate [61]. This process is regulated by several mechanisms, such as
self-interaction, polymerization, phosphorylation, aggregation,
and binding to ubiquitinated targets [61]. In fact, nuclear
accumulation of SQSTM1 was observed in Hela cells treated
with LMB [62]. Alternatively, SQSTM1 was shown to be a
negative regulator of the ras signaling pathway [60]. Since A549
contains K-ras mutation, the increase and nuclear accumulation of
SQSTM1 in A549 cells after LMB treatment might further
inactivate functional K-ras that resulted in cell growth inhibition.
Until recently, the function of SQSTM1 in the nucleus has been
rarely addressed. It has been suggested that nuclear SQSTM1
could be directly associated with chromatin [62], or play a role in
regulating gene transcription [63]. SQSTM1 has been reported to
interact with p53; the accumulation of SQSTM1 could slow the
clearance of short lived ubiquitin-proteasome system specific
substrates, such as p53 [64]. Nuclear accumulation of proteins as
observed in LMB-treated A549 cells, especially when pre-DOX
was added, suggests that DOX and LMB may lead to nuclear
sequestration of CRM1 cargo proteins, such as SQSTM1, in
regulating cell growth/proliferation/apoptosis.
In summary, the present study found that combination therapy
of pretreatment with DOX followed by LMB treatment
significantly increased the efficacy of LMB through p53 and
potentially other molecular pathways involving sequestosome 1.
Future studies of other molecular mechanisms as well as CRM1
mutations/instability/integrity are necessary to further elucidate
the usefulness of LMB and/or its derivatives for clinical
application. Nevertheless, our data have essential predictive and
therapeutic implications that could provide a promising basis for
preclinical and/or clinical trials on lung cancer treatment.
Supporting Information
Figure S1 Cytotoxic effects of DOX and LMB on NCI-
H358 cells. A, Cytotoxic effects of DOX alone and DOX+LMB
on cell viability of NCI-H358 cells as determined by the MTT
assay. Data are expressed as the percentage by comparing to
vehicle control for DOX and LMB (0.5 nM) for DOX+LMB.
Values are represented as means 6 SD, n=6. B, Cytotoxic effects
of LMB alone and LMB+DOX on cell viability of NCI-H358 cells
as determined by the MTT assay. Data are expressed as the
percentage by comparing to vehicle control for LMB and DOX
(0.5 mM) for LMB+DOX. Values are means 6 SD, n=6. C,
Cytotoxic effects of DOX alone and pre-LMB+DOX on cell
viability of NCI-H358 cells at 48 h as determined by the MTT
assay. Data are expressed as the percentage by comparing to
vehicle control for DOX and pre-LMB for pre-LMB+DOX.
Values are means 6 SD, n=6. D, Cytotoxic effects of LMB alone
and pre-DOX+LMB on cell viability of NCI-H358 cells at 48 h as
determined by the MTT assay. Data are expressed as the
percentage by comparing to vehicle control for LMB and pre-
DOX for pre-DOX+LMB. Values are means 6 SD, n=6.
Experiments performed in triplicate yielded similar results.
(TIF)
Figure S2 Nuclear proteome profiling in NCI-H358 cells
after DOX and/or LMB treatment. A, Western blot of
nuclear and cytoplasmic protein extractions from NCI-H358; a-
tubulin served as an internal control for cytoplasmic proteins, and
histone 3 served as a control for nuclear proteins. B, 2D-DIGE
analyses of nuclear proteins in NCI-H358 cells with vehicle control
or LMB treatment. Nuclear proteins treated with LMB or vehicle
control were labeled with Cy3 (green channel) and Cy5 (red
channel), respectively. Nuclear proteins were separated based on
isoelectric point (PI, horizontal axis) and molecular weight (MW,
vertical axis). Approximately 1,000 protein spots were detected in
nuclear extractions of NCI-H358 cells. Spots labeled with red
color indicate decreased expression after LMB treatment, while
spots labeled with green color indicate increased expression after
LMB treatment. C, Western blot analysis of SQSTM1 in
cytoplasm and nucleus of NCI-H358 cells after LMB treatment.
(TIF)
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